skip to main content

Elan reports net loss of $13.8m for Q3

Shareholders will next month vote on Perrigo's proposed acquisition of Elan
Shareholders will next month vote on Perrigo's proposed acquisition of Elan

Irish pharmaceutical company Elan has reported a net loss of $13.8 million for the third quarter.

That was down to continuing operations associated with the planned company buyout, according to a statement from the company.

Elan shareholders will get an opportunity to vote on Perrigo's proposed acquisition of the company in Dublin next month.

Earnings Before interest Taxes and Depreciations of $12.1 million was recorded for the third quarter, reflecting the first full quarter of the new royalty arrangements on Tysabri.

The company ended the quarter with almost $1.9 billion in cash and cash equivalents, and no debt.